Dr. Stephen Andrew Mihalcik, MD, PhD

Dr. Mihalcik practices at Ann & Robert H. Lurie Children's Hospital of Chicago in Chicago, Illinois, part of Ann & Robert H. Lurie Children's Hospital of Chicago.

Dr. Mihalcik's NPI, 1598031205, was assigned on March 27, 2012. Dr. Mihalcik graduated from Mayo Medical School in 2012. Dr. Mihalcik holds Illinois license 036142451.

Dr. Mihalcik's primary practice is Ann & Robert H. Lurie Children's Hospital of Chicago, at 225 E Chicago Ave, Box 140, Chicago, IL 60611 in Cook County. The practice phone is (312) 227-4000.

Dr. Mihalcik's primary practice is Ann & Robert H. Lurie Children's Hospital of Chicago in Chicago, Illinois, part of Ann & Robert H. Lurie Children's Hospital of Chicago. Dr. Mihalcik is also affiliated with Massachusetts General Hospital. The medical group on file is Massachusetts General Physicians Organization (MGPO). Dmand AI also links Dr. Mihalcik to 3 more hospitals, 3 medical groups and 1 clinical lab, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mihalcik practices, 6 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Mihalcik's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Mihalcik is licensed in Illinois.

CMS data shows 2,256 Medicare services from Dr. Mihalcik across 16 procedure codes in 2024, for 587 Medicare patients. Medicare paid $137,984 for them. Every service was in an office.

CMS counts 587 Medicare patients who saw Dr. Mihalcik in 2024. The largest group is 65 to 74, with 318 patients. 75% of them have cancer, and 72% have high cholesterol. 6% are also on Medicaid. Their average risk score is 1.41, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Mihalcik's median patient age at 68, with 36% women.

In 2024, Dr. Mihalcik wrote 140 Medicare Part D claims for 78 patients. 96% of them were for generic drugs. CMS names the drug for 87 of them, across 3 drugs with 11 or more claims each, at $1,159 in total drug cost. In 2023, CMS named 74 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Dr. Mihalcik for performance year 2024, reported through an alternative payment model (APM). Dr. Mihalcik accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 9 papers to Dr. Mihalcik, published from 2016 to 2025. 2025 was the busiest year, with 3. The most frequent topics are Prostatic Neoplasms, Proton Therapy and Brachytherapy. Dr. Mihalcik has published most often in Pract Radiat Oncol. Dr. Mihalcik's most frequent co-authors are Ralph Philip Ermoian, MD, Nadia Nicole Issa Laack, MD and Daniel J. Indelicato, MD.

Dmand AI links Dr. Mihalcik to 2 clinical trials. 2 are still active or recruiting. Conditions studied include Adenocarcinoma Of Esophagus, Carcinoma, Intraductal, Noninfiltrating and Breast Carcinoma In Situ.

CMS Open Payments shows 7 general payments to Dr. Mihalcik from 5 drug and device companies from 2018 to 2024. Food and beverage make up the largest share, 51% of the total. Ion Beam Applications S.A. paid the most, $2,435.

Dr. Mihalcik graduated from Mayo Medical School in 2012.